MODULATION THERAPEUTICS
Modulation Therapeutics is dedicated towards the rapid and cost effective advancement of early stage first in class molecules targeting the tumor microenvironment. Tumors that home or metastasize to the bone are typically difficult to treat with standard chemotherapy. We propose that strategies to eradicate tumors that home or metastasize to the bone marrow compartment must include disrupting tumor-host interactions. Our lead compound MTI-101 targets CD44, a cell adhesion molecule required for ... homing to the bone. Our compound shows activity as a single agent using myeloma in vivo models. We project IND filing of our lead compound MTI-101 in the fourth quarter of 2013. Our goal is to develop the lead compound for the treatment of Myeloma a plasma cell tumor which homes to the bone and a disease which currently has no curative therapies available
MODULATION THERAPEUTICS
Industry:
Biotechnology
Founded:
2011-01-01
Address:
Tampa, Florida, United States
Country:
United States
Website Url:
http://www.modulationtherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
8137457264
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
SPF Google Font API LetsEncrypt WordPress Domain Not Resolving Apache Wordpress Plugins Google Apps For Business WooCommerce Unified Layer
Similar Organizations
Arno Therapeutics
Arno Therapeutics is a biopharmaceutical company developing innovative products for the treatment of cancer patients.
Mast Therapeutics
Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Current Employees Featured
Founder
Investors List
Florida Institute for the Commercialization of Florida Technology
Florida Institute for the Commercialization of Florida Technology investment in Seed Round - Modulation Therapeutics
Official Site Inspections
http://www.modulationtherapeutics.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Modulation Therapeutics"
Modulation Therapeutics - Crunchbase Company …
Modulation Therapeutics is a pharmaceutical company developing novel compounds for the treatment of multiple myeloma. View contacts for Modulation Therapeutics to access new leads and connect with decision-makers.See details»
Modulation Therapeutics | Seed - National Institutes of Health
Modulation Therapeutics is a clinical-stage company dedicated to bringing novel therapeutics to the treatment of cancer patients. Its lead molecule, MTI-201, is currently in a Phase I clinical …See details»
Modulation Therapeutics - LinkedIn
Modulation Therapeutics is dedicated towards the rapid and cost effective advancement of early stage first in class molecules targeting the tumor microenvironment.See details»
Modulation Therapeutics - VentureRadar
Website: http://www.modulationtherapeutics.com. Modulation Therapeutics is dedicated towards the rapid and cost effective advancement of early stage first in class molecules targeting the …See details»
Modulation Therapeutics, Inc. - Drug pipelines, Patents, Clinical ...
Our group has developed a novel agent cyclic peptide called MTI-101 for the treatment of MM. MTI-101 was optimized form the D-amino acid linear peptide HYD-1 (1). HYD-1 and the more …See details»
MODULATION THERAPEUTICS, INC. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for MODULATION THERAPEUTICS, INC. of Morgantown, WV. Get the latest business insights from Dun & …See details»
Modulation Therapeutics - PitchBook
Operator of a biotechnology company intended to develop therapies to defeat aggressive forms of solid tumor cancers and liver disease. The company's service includes drug discovery, …See details»
Modulation Therapeutics Inc - Company Profile and News
The Company develops a drug with a novel mechanism of action for myeloma, an incurable blood cancer, as well as conducts studies to understand the dosing, toxicology, and optimal clinical...See details»
Modulation Therapeutics - LinkedIn
Modulation Therapeutics is a pharmaceutical company in Morgantown, WV, United States.See details»
Modulation Therapeutics - Overview, News & Similar companies
Modulation Therapeutics contact info: Phone number: (304) 241-4584 Website: www.modulationtherapeutics.com What does Modulation Therapeutics do? Modulation …See details»
RePORT 〉 RePORTER - National Institutes of Health
Modulation Therapeutics is developing a stearoyl- coenzyme A desaturase-1 (SCD1) inhibitor for the treatment of NAFLD and NASH. The novel lead molecule referred to as MTI-301 is orally …See details»
Modulation Therapeutics Receives Seed Funding through Florida …
Feb 15, 2013 · Modulation Therapeutics, based on technology licensed from the Moffitt Cancer Center in Tampa, focuses on cancers such as multiple myeloma that home or metastasize to …See details»
Modulation Therapeutics - Contacts, Employees, Board Members, …
Modulation Therapeutics has 3 current employee profiles, including Founder & Executive Vice President Mark McLaughlin. Modulation Therapeutics is a pharmaceutical company …See details»
Modulation Therapeutics, Inc. | Morgantown WV - Facebook
Modulation Therapeutics is a drug discovery and research company with a suite of novel peptidomimetic drugs that target cancers that home to the bone.See details»
Mark McLaughlin - Founder & Executive Vice President - Crunchbase
Dr. McLaughlin has a 50/50 appointment serving as Professor of Chemistry at the University of South Florida, a Senior Member of the Drug Discovery Department at the Moffitt Cancer …See details»
WVU gets FDA approval for clinical trial of d | EurekAlert!
Mark McLaughlin —a researcher with the WVU Cancer Institute and Modulation Therapeutics Inc.—and his colleagues are developing a cancer treatment that zeroes in on the diseased …See details»
Modulation Therapeutics obtains FDA approval to trial eye cancer …
Nov 9, 2021 · The US Food and Drug Administration (FDA) has approved investigational new drug application of Modulation Therapeutics to commence human trial of its drug, MTI-201, to …See details»
FDA approve clinical trial of drug to treat eye cancer ‘from the …
Nov 11, 2021 · An early discovery and translational drug development company, Modulation Therapeutics is housed in the Cancer Institute and received funding from the National Cancer …See details»
Development of PEGylated MTI-101 for the treatment of
Sep 1, 2019 · Modulation Therapeutics is developing a first in class cyclic peptide coined MTI-101 for the treatment of multiple myeloma. The company currently has a license for the parent …See details»
Drug To Treat Eye Cancer Set To Begin Clinical Trials
Nov 9, 2021 · This is the first investigational new drug application that the FDA has awarded Modulation Therapeutics. Down the line, it’s possible that MTI-201 could even be used to treat …See details»